Revenio Group (REG1V) CMD 2026 summary
Event summary combining transcript, slides, and related documents.
CMD 2026 summary
23 Sep, 2026Strategic direction and market positioning
Transitioning from traditional vision care to connected eye health, leveraging device and software innovations and an expanded portfolio after the Visionix acquisition.
Addressable market expanded from EUR 1.1 billion to EUR 2.7 billion (or $2.7 billion) and strengthened global presence through Visionix.
Four strategic cornerstones: advancing clinical confidence and workflow excellence, expanding product and software integration, operational excellence, and people/culture development.
Strategy builds on previous focus on connected and predictive eye care, now emphasizing sustainable, profitable growth and global reach.
Differentiators include efficiency, clinical confidence, ease of use, and innovation across a broad, integrated portfolio.
Product and solution portfolio
Comprehensive offering spans essential to advanced diagnostics, including tonometry, fundus imaging, OCT, perimetry, and cloud-based solutions.
Integration of cloud platforms enables modular, customer-facing solutions, seamless data flow, and AI-supported decision-making.
Portfolio enables clinical role expansion for optical retail and optometry, supporting broader access and workflow excellence.
Continuous innovation and integration of Visionix products enhance the value proposition.
R&D investment to remain around 10% of revenue, balancing hardware and software innovation.
Commercial and operational integration
Combined commercial footprint enables stronger direct sales, cross-selling, and broader customer access, especially in U.S. and Europe.
Distribution network optimized with over 400 distributors in 130+ markets, focusing on strategic alignment and execution.
Operational excellence initiatives include simplifying the supply chain, harmonizing customer care, and strengthening quality culture.
Unified culture and high-performing organization prioritized, with ongoing integration and employee engagement efforts.
Employee experience, growth, and a one-company culture are prioritized.
Latest events from Revenio Group
- EUR 80 million rights offering approved, with subscription period from September 28 to October 12, 2026.REG1V
Status update - Q2 net sales up 48.1% as Visionix boosted growth but pressured margins and leverage.REG1V
Q2 2026 - Net sales rose 4.8% but profit dropped on Visionix costs; acquisition expands market reach.REG1V
Q1 2026 - Merger forms a top global eye care leader, targeting EUR 20m+ synergies and rapid growth.REG1V
M&A announcement - 2025 net sales up 6% to EUR 109.7M, record cash flow, and 2026 sales growth expected at 8–15%.REG1V
Q4 2025 - Q3 2025 saw strong sales and profitability, with 6–15% sales growth forecast for 2025.REG1V
Q3 2025 - Q3 net sales up 8.9%, operating profit down, AI diagnostics strengthened by Thirona Retina.REG1V
Q3 2024 - Q2 net sales up 14.2%, strong cash flow, and 2024 sales growth guidance of 5–10%.REG1V
Q2 2024 - Record Q1 sales and profit, driven by global growth and strong financials.REG1V
Q1 2025